Literature DB >> 29210653

Human Umbilical Cord Mesenchymal Stem Cells: Subpopulations and Their Difference in Cell Biology and Effects on Retinal Degeneration in RCS Rats.

L Wang1, P Li2, Y Tian2, Z Li2, C Lian2, Q Ou2, C Jin2, F Gao2, J-Y Xu2, J Wang2, F Wang1, J Zhang2, J Zhang2, W Li2, H Tian2, L Lu2, G-T Xu2.   

Abstract

BACKGROUND: Human umbilical cord mesenchymal stem cells (hUC-MSCs) are potential candidates for treating retinal degeneration (RD).
OBJECTIVE: To further study the biology and therapeutic effects of the hUC-MSCs on retinal degeneration.
METHODS: Two hUC-MSC subpopulations, termed hUC-MSC1 and hUC-MSC2, were isolated by single-cell cloning method and their therapeutic functions were compared in RCS rat, a RD model.
RESULTS: Although both subsets satisfied the basic requirements for hUC-MSCs, they were significantly different in morphology, proliferation rate, differentiation capacity, phenotype and gene expression. Furthermore, only the smaller, fibroblast-like, faster growing subset hUC-MSC1 displayed stronger colony forming potential as well as adipogenic and osteogenic differentiation capacities. When the two subsets were respectively transplanted into the subretinal spaces of RCS rats, both subsets survived, but only hUC-MSC1 expressed RPE cell markers Bestrophin and RPE65. More importantly, hUC-MSC1 showed stronger rescue effect on the retinal function as indicated by the higher b-wave amplitude on ERG examination, thicker retinal nuclear layer, and decreased apoptotic photoreceptors. When both subsets were treated with interleukin-6, mimicking the inflammatory environment when the cells were transplanted into the eyes with degenerated retina, hUC-MSC1 expressed much higher levels of trophic factors in comparison with hUC-MSC2.
CONCLUSION: The data here, in addition to prove the heterogeneity of hUC-MSCs, confirmed that the stronger therapeutic effects of hUC-MSC1 were attributed to its stronger anti-apoptotic effect, paracrine of trophic factors and potential RPE cell differentiation capacity. Thus, the subset hUC-MSC1, not the other subset or the ungrouped hUC-MSCs should be used for effective treatment of RD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Human umbilical cord mesenchymal stem cells; antiapoptoticzzm321990effect; cell differentiation; paracrine.; retinal degeneration; stem cell subpopulation

Mesh:

Year:  2017        PMID: 29210653     DOI: 10.2174/1566524018666171205140806

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  9 in total

1.  Overexpression of pigment epithelium-derived factor in placenta-derived mesenchymal stem cells promotes mitochondrial biogenesis in retinal cells.

Authors:  Jae Yeon Kim; Sohae Park; So Hyun Park; Dongsook Lee; Gyu Hyun Kim; Jung Eun Noh; Kea Joo Lee; Gi Jin Kim
Journal:  Lab Invest       Date:  2020-07-28       Impact factor: 5.662

2.  Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results.

Authors:  Emin Özmert; Umut Arslan
Journal:  Stem Cell Res Ther       Date:  2020-01-13       Impact factor: 6.832

3.  Intravenous infusion of small umbilical cord mesenchymal stem cells could enhance safety and delay retinal degeneration in RCS rats.

Authors:  Qingling Liang; Qiyou Li; Bangqi Ren; Zheng Qin Yin
Journal:  BMC Ophthalmol       Date:  2022-02-11       Impact factor: 2.209

4.  Human pluripotent stem cell-derived ectomesenchymal stromal cells promote more robust functional recovery than umbilical cord-derived mesenchymal stromal cells after hypoxic-ischaemic brain damage.

Authors:  Jiawei Huang; Kin Pong U; Fuyuan Yang; Zeyuan Ji; Jiacheng Lin; Zhihui Weng; Lai Ling Tsang; Tobias D Merson; Ye Chun Ruan; Chao Wan; Gang Li; Xiaohua Jiang
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

5.  Direct conversion of human umbilical cord mesenchymal stem cells into retinal pigment epithelial cells for treatment of retinal degeneration.

Authors:  Xiaoman Zhu; Zhiyang Chen; Li Wang; Qingjian Ou; Zhong Feng; Honglei Xiao; Qi Shen; Yingao Li; Caixia Jin; Jing-Ying Xu; Furong Gao; Juan Wang; Jingfa Zhang; Jieping Zhang; Zhiguo Xu; Guo-Tong Xu; Lixia Lu; Haibin Tian
Journal:  Cell Death Dis       Date:  2022-09-12       Impact factor: 9.685

6.  Induced retinal pigment epithelial cells with anti-epithelial-to-mesenchymal transition ability delay retinal degeneration.

Authors:  Haibin Tian; Zhiyang Chen; Xiaoman Zhu; Qingjian Ou; Zhe Wang; Binxin Wu; Jing-Ying Xu; Caixia Jin; Furong Gao; Juan Wang; Jingfa Zhang; Jieping Zhang; Lixia Lu; Guo-Tong Xu
Journal:  iScience       Date:  2022-09-02

7.  Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results.

Authors:  Emin Özmert; Umut Arslan
Journal:  Stem Cell Res Ther       Date:  2020-08-12       Impact factor: 6.832

8.  The cGAS/STING pathway: a sensor of senescence-associated DNA damage and trigger of inflammation in early age-related macular degeneration.

Authors:  Yan Wu; Qingquan Wei; Jing Yu
Journal:  Clin Interv Aging       Date:  2019-07-11       Impact factor: 4.458

9.  Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration.

Authors:  Chun-Lei Deng; Cheng-Biao Hu; Sheng-Tao Ling; Na Zhao; Li-Hui Bao; Feng Zhou; Ye-Cheng Xiong; Tao Chen; Bing-Dong Sui; Xiao-Rui Yu; Cheng-Hu Hu
Journal:  Cell Death Differ       Date:  2020-10-20       Impact factor: 15.828

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.